Source:http://linkedlifedata.com/resource/pubmed/id/10029452
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1999-3-2
|
| pubmed:abstractText |
We histologically examined undifferentiated small cell carcinoma of the esophagus from 21 patients and used immunohistochemical methods for detection of chromogranin A and p53, bcl-2, and Rb oncoproteins. Nine (43%) of the 21 carcinomas consisted solely of undifferentiated cells, but heterogeneous components of in situ or invasive squamous cell carcinoma or mucoepidermoid carcinoma were observed in the other 12 (57%) tumors. Squamous cell carcinoma in situ was observed in the mucosa adjacent to the main tumor in 7 (50%) of the 14 resected esophageal specimens. An admixture of invasive squamous cell carcinoma and undifferentiated carcinoma was observed in 4 (19%) of the 21 tumors, and mucoepidermoid carcinoma was noted in one case. Chromogranin A staining yielded a positive reaction in two (10%) undifferentiated components but was negative in all heterogeneous components. Multiple sites of p53 immunopositivity were seen in the undifferentiated component of 17 (81%) of the 21 tumors, as well as in the in situ or invasive squamous cell carcinoma or mucoepidermoid carcinoma components of 9 (75%) of 12 tumors. Seven (33%) of the 21 tumors showed positive bcl-2 immunoreactivity in the small cell component, but all of the heterogeneous components were negative. Rb protein immunoreactivity was observed in the small cell component of one (5%) case and in 9 (75%) of the 12 heterogeneous components. Six (86%) of the seven in situ squamous cell carcinoma components were positive for Rb protein. Eighteen (86%) of the 21 patients died within 24 months of diagnosis. Two patients (10%) who survived for more than 24 months had received chemotherapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Chromogranin A,
http://linkedlifedata.com/resource/pubmed/chemical/Chromogranins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Retinoblastoma Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0046-8177
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
30
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
216-21
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10029452-Aged,
pubmed-meshheading:10029452-Aged, 80 and over,
pubmed-meshheading:10029452-Carcinoma, Small Cell,
pubmed-meshheading:10029452-Carcinoma, Squamous Cell,
pubmed-meshheading:10029452-Carcinoma in Situ,
pubmed-meshheading:10029452-Chromogranin A,
pubmed-meshheading:10029452-Chromogranins,
pubmed-meshheading:10029452-Esophageal Neoplasms,
pubmed-meshheading:10029452-Female,
pubmed-meshheading:10029452-Humans,
pubmed-meshheading:10029452-Immunohistochemistry,
pubmed-meshheading:10029452-Male,
pubmed-meshheading:10029452-Middle Aged,
pubmed-meshheading:10029452-Neoplasms, Multiple Primary,
pubmed-meshheading:10029452-Prognosis,
pubmed-meshheading:10029452-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:10029452-Retinoblastoma Protein,
pubmed-meshheading:10029452-Survival Rate,
pubmed-meshheading:10029452-Tumor Suppressor Protein p53
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Primary undifferentiated small cell carcinoma of the esophagus.
|
| pubmed:affiliation |
Department of Clinical Pathology, Tokyo Metropolitan Institute of Gerontology, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|